Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience

Table 1 Clinical features of patients with MwoA

Parameter	Timing	Mean ± SE	p value
Gender		15 F/5 M
Age (years)		32.9 ± 2.3
Disease duration (years)		8.3 ± 1.7
Frequency (days/month)	Baseline	4.5 ± 0.24	< 0.001
Frequency (days/month)	Follow-up	2.06 ± 0.28	< 0.001
NSAID intake (including acetaminophen)	Baseline	3.2 ± 0.6	0.02
NSAID intake (including acetaminophen)	Follow-up	1.3 ± 0.4	0.02
Triptans intake	Baseline	2.4 ± 0.7	0.04
Triptans intake	Follow-up	0.9 ± 0.3	0.04
Total intake of rescue medication	Baseline	5.6 ± 0.4	< 0.001
Total intake of rescue medication	Follow-up	2.2 ± 0.3	< 0.001
HIT-6	Baseline	62.3 ± 1.4	< 0.001
HIT-6	Follow-up	53.1 ± 1.4	< 0.001
VAS of attack intensity	Baseline	8.0 ± 0.1	0.002
VAS of attack intensity	Follow-up	6.7 ± 0.2	0.002

F female, M male, NSAID non-steroidal anti-inflammatory drugs, HIT-6 Headache Impact Test, VAS Visual Analogue Scale

ISSN: 1129-2377